# BAY1436032 in Patients With Mutant IDH1(mIDH1) Advanced Acute Myeloid Leukemia (AML)

> **NCT03127735** · PHASE1 · COMPLETED · sponsor: **Bayer** · enrollment: 27 (actual)

## Conditions studied

- Leukemia, Myeloid, Acute

## Interventions

- **DRUG:** BAY1436032

## Key facts

- **NCT ID:** NCT03127735
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-06-14
- **Primary completion:** 2018-12-06
- **Final completion:** 2019-03-15
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2019-05-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03127735

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03127735, "BAY1436032 in Patients With Mutant IDH1(mIDH1) Advanced Acute Myeloid Leukemia (AML)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03127735. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*